<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01894165</url>
  </required_header>
  <id_info>
    <org_study_id>ALXN1101-MCD-101</org_study_id>
    <nct_id>NCT01894165</nct_id>
  </id_info>
  <brief_title>Phase 1 Single Dose Study of ALXN1101 in Healthy Volunteers</brief_title>
  <official_title>A Phase 1, Randomized, Blinded, Placebo-Controlled, Single-Dose, Sequential-Cohort, Dose-Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ALXN1101 in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexion Pharma GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alexion Pharma GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 1 single dose study of ALXN1101 in healthy volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a first-in-human (FIH), randomized, blinded, placebo-controlled, single-dose,
      sequential-cohort, dose-escalation study to evaluate the safety, tolerability, and
      pharmacokinetics (PK) of a single dose of ALXN1101 in healthy adult subjects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of single dose of ALXN1101 in healthy adult subjects</measure>
    <time_frame>following the Day 30 visit for the last study subject</time_frame>
    <description>Physical examination, vital signs, ECGs, laboratory evaluations, and Adverse Events.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK parameters of ALXN1101</measure>
    <time_frame>following the Day 5 visit for the last study subject</time_frame>
    <description>PK parameters of ALXN1101 will be estimated including, but not limited to,maximum observed plasma concentration (Cmax), time to maximum observed plasma concentration (tmax), terminal elimination halflife (t½), area under the plasma concentration-time curve (AUC), total body clearance (CL), and volume of distribution (Vd).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Exploratory biochemical marker assessments</measure>
    <time_frame>following the Day 30 visit for the last study subject</time_frame>
    <description>To evaluate urine, serum or plasma concentrations of biochemical markers including S-sulfocysteine, xanthine, uric acid, creatinine, and other exploratory biochemical markers.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Molybdenum Cofactor Deficiency (MoCD)</condition>
  <condition>Rare Autosomal Recessive Disorder</condition>
  <condition>Deficiency of Activity of Molybdenum-dependent Enzymes (Sulfite Oxidase [SOX], Xanthine Dehydrogenase, and Aldehyde Oxidase)</condition>
  <arm_group>
    <arm_group_label>ALXN1101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Four cohorts planned. Within each cohort, healthy volunteers are randomized to ALXN1101 IV single dose or placebo IV single dose. Each subsequent cohort is testing an increased dose of ALXN1101 IV or placebo IV.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Four cohorts planned. Within each cohort, healthy volunteers are randomized to ALXN1101 IV single dose or placebo IV single dose. Each subsequent cohort is testing an increased dose of ALXN1101 IV or placebo IV.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALXN1101</intervention_name>
    <description>Randomized to receive a single dose of ALXN1101 or placebo as per assigned cohort dose level.</description>
    <arm_group_label>ALXN1101</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Randomized to receive a single dose of ALXN1101 or placebo as per assigned cohort dose level.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. Male or female subjects ≥ 18 and ≤ 60 years of age and weight ≥ 55 kg and ≤ 100 kg

          2. Willing and able to give written informed consent

          3. Female subjects of child bearing potential must have a negative serum pregnancy test
             or must be practicing an approved contraceptive regimen for the duration of the study

          4. Male subjects must be practicing an acceptable barrier method of contraception

        Key Exclusion Criteria:

          1. Pregnant or nursing female subjects

          2. QTcF &gt; 450 msec for males and &gt; 470 msec for females, or a family history of Long QT
             Syndrome.

          3. CrCl &lt; 80 mL/min

          4. CBC in acceptable range; SGOT or SGPT above the ULN

          5. HIV, Hepatitis B or Hepatitis C virus infection

          6. Other active systemic infection or malignancy

          7. Investigational drug study within 60 days

          8. Major surgery within the prior 90 days

          9. History of illicit drug use or chronic alcohol dependence within 2 years prior to this
             study

         10. Positive urine drug toxicology screen or serum alcohol test

         11. Alcohol consumption within 48 hours prior to study drug administration

         12. Recently donated or lost ≥ 499 mL of blood

         13. Recent hormone replacement therapy or use of prescription medications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald Goldwater, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Parexel Baltimore Early Phase Clinical Unit</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Parexel Baltimore EPCU</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 27, 2013</study_first_submitted>
  <study_first_submitted_qc>July 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 10, 2013</study_first_posted>
  <last_update_submitted>November 5, 2013</last_update_submitted>
  <last_update_submitted_qc>November 5, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 6, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>molybdenum cofactor deficiency (MoCD)</keyword>
  <keyword>deficiency of activity of molybdenum-dependent enzymes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metal Metabolism, Inborn Errors</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Molybdenum</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

